Abivax publishes financial reports with the french and u.s. securities regulatory agencies

Abivax publishes financial reports with the french and u.s. securities regulatory agencies paris, france – march 26, 2025 – 10:05 pm cet – abivax sa (euronext paris & nasdaq: abvx) (“abivax” or the “company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its universal registration document (document d'enregistrement universel) with the french financial market authorities, autoritÉ des marchÉs financiers (amf), and the filing of its annual report (20-f) with the u.s. securities and exchange commission (sec) on march 24, 2025. the universal registration document includes the 2024 annual financial report, the management report including the report on corporate governance, as well as the reports of the statutory auditors.
ABVX Ratings Summary
ABVX Quant Ranking